Bausch + Lomb Progresses Development of Oral Treatment for Dry AMD

Bausch + Lomb Corporation, headquartered in Vaughan, Ontario, is making strides in eye health with its development of BL1243 (tonabersat), an investigational oral treatment targeting early-stage dry age-related macular degeneration (AMD). Currently, treatment options for patients with this condition are quite limited, making this development significant. The announcement follows a constructive meeting with the U.S. Food and Drug Administration (FDA), which provided essential guidance on the clinical development trajectory for the new treatment. The clinical development program for BL1243 is anticipated to commence in 2027. As a prominent player in the eye health market, Bausch + Lomb's advancements may have a considerable impact on patients dealing with AMD, contributing to the options available for managing the condition.